What changed in this filing

/stocks — the workspaceLOADING

Item 1. Business

2021-10-29 compared with 2020-11-16 · 246 added, 202 removed, 41 unchanged (92% of the section changed)

This Annual Report

on Form 10-K contains forward-looking statements based on expectations, estimates, and projections as of the date of this filing.

Actual results may differ materially from those expressed in forward-looking statements.

See Item 1A of Part I—“Risk

Factors.”

This Annual Report on Form

10-K contains forward-looking statements based on expectations, estimates, and projections as of the date of this filing.

Actual results

may differ materially from those expressed in forward-looking statements.

See Item 1A of Part I—“Risk Factors.”

Odyssey Group International,

was formed as a Nevada corporation in March 2014.

Our principal executive offices are located at 2372 Morse Ave., Irvine,

Our principal executive offices are located at 2372 Morse Ave., Irvine, CA 92614.

The registration statement effectuating our initial public offering became effective in July 2015.

Our shares of common

stock are listed on the OTCQB Marketplace (“OTC”) and there is currently very little public market for our common stock.

As used herein, when

we refer to “Odyssey”, “ODYY,”

Our shares of common stock

are listed on the OTCPink Marketplace (“OTC”) and there is currently very little public market for our common stock.

As used herein, when we refer

to “Odyssey”, “ODYY,”

the “Company,”

3 unchanged sentences

and “our,”

we mean Odyssey Group International, Inc., a Nevada corporation, unless the context indicates

Recently the United

States Congress passed the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), which provides for certain

exemptions from various reporting requirements applicable to public companies that are reporting companies and are “emerging

growth companies.”

We are an “emerging growth company”

as defined in Section 3(a) of the Exchange Act (as amended

by the JOBS Act, enacted on April 5, 2012), and we will continue to qualify as an “emerging growth company”

earliest to occur of:

(a) the last day of the fiscal year during which we have total annual gross revenues of $1,000,000,000 (as

such amount is indexed for inflation every five years by the SEC) or more;

(b) the last day of our fiscal year following the fifth

anniversary of the date of the first sale of our common equity securities pursuant to an effective registration statement under

the Securities Act;

or (d) the date on which we are deemed to be a “large accelerated filer,”

as defined in Exchange Act Rule 12b–2.

Generally, a registrant

that registers any class of its securities under Section 12 of the Exchange Act is required to include in the second and all subsequent

annual reports filed by it under the Exchange Act a management report on internal control over financial reporting and, subject

to an exemption available to registrants that meet the definition of a “smaller reporting company”

in Exchange Act

Rule 12b-2, an auditor attestation report on management’s assessment of internal control over financial reporting.

for so long as we continue to qualify as an emerging growth company, we will be exempt from the requirement to include an auditor

attestation report in our annual reports filed under the Exchange Act, even if we do not qualify as a “smaller reporting

company”.

In addition, as an emerging growth company, we are able to avail ourselves to the reduced disclosure obligations

regarding executive compensation in our periodic reports and proxy statements and not to present to our stockholders a nonbinding

advisory vote on executive compensation, obtain approval of any golden parachute payments not previously approved or present the

relationship between executive compensation actually paid and our financial performance.

We have irrevocably elected to comply

with new or revised accounting standards even though we are an emerging growth company.

Odyssey was formed

as a publicly held holding company with an emphasis on the development and acquisition of medical products and health related technologies.

We are focused on building and acquiring technologies that have a technological advantage and a substantial market opportunity

within significant target markets across the globe.

The corporate mission is to create or acquire distinct technologies and intellectual

property with an emphasis on acquisition targets that will generate positive cash flow.

Our strategic mission is to deliver financial

results, which yield high rates of returns for our shareholders and partners.

The Company’s leadership team has significant

experience and capabilities to further refine the technologies and submit to the appropriate regulatory agencies for marketing

Our business model

is to develop or acquire medical related products, engage third parties to manufacture such products and then distribute the products

through various distribution channels, including third parties.

The Company has product development projects in three different

life saving technologies;

we mean Odyssey Group International, Inc., a Nevada corporation, unless the context indicates otherwise.

Odyssey is a publicly held

holding company with an emphasis on the development and acquisition of medical products and health related technologies.

We are focused

on developing and acquiring technologies that have a technological advantage and a substantial market opportunity within significant target

markets across the globe.

The corporate mission is to create or acquire distinct technologies and intellectual property with an emphasis

on acquisition targets that will generate positive cash flow.

Our strategic mission is to deliver financial results, which yield high

rates of returns for our shareholders and partners.

Our leadership team has significant experience and capabilities to commercialize our

technologies and submit to the appropriate regulatory agencies for marketing approval.

Our business model is to develop or acquire unique medical related products, engage

third parties to manufacture such products and then distribute the products through various distribution channels, including third parties.

We are developing potentially life-saving technologies:

the CardioMap®

heart monitoring and screening device, the Save A Life choking rescue device and a

unique neurosteroid drug compound intended to treat rare brain disorders.

We intend to acquire

other technologies and assets and plan to be a multi-disciplinary product development company involved in the discovery, development

and commercialization of products and technologies that may be applied over various medical markets.

We intend to license,

improve and/or develop our products and identify and select distribution channels.

We intend to establish agreements with distributors

to get products to market quickly as well as to undertake and engage in our own direct marketing efforts.

We will determine the

most effective method of distribution for each unique product that we include in our portfolio.

We intend to engage

third party research and development firms who specialize in the creation of medical products to assist us in the development.

We intend to apply for trademarks and patents as we develop proprietary products.

For a complete description

of our business, financial condition, results of operations and other important information, we refer you to our filings with the

SEC that are incorporated by reference in this Annual Report, including our Annual

Report on Form 10-K for the year ended July 31, 2019 and our Quarterly

Reports on Form 10-Q for the periods ended October 31, 2019, January 31, 2020 and April 30, 2020, as amended by the filings

of Form 10K/A for the period ended July 31, 2019 and Quarterly Reports on Form 10-Q/A for the periods ended October 31, 2019, January

31, 2020 and April 30, 2020 filed and with the Securities and Exchange Commission on November 13, 2020.

For instructions on how

to find copies of these documents, see the section entitled “Where You Can Find More Information”.

Financial Information about Industry

We do not report our

revenues or expenses by segment.

heart monitoring and screening device;

the Save A Life choking

rescue device;

PRV-001 and PRV-002 which are unique neurosteroid drug compounds intended to treat concussions and rare brain disorders.

To date, none of our product candidates has received regulatory clearance or approval for commercial sale.

We intend to acquire other

technologies and assets and plan to be a trans-disciplinary product development company involved in the development and commercialization

of products and technologies that may be applied over various medical markets.

We intend to license, improve

and/or develop our products and identify and select distribution channels.

We plan to establish agreements with distributors to get products

to market quickly as well as to undertake and engage in our own direct marketing efforts.

We will determine the most effective method

of distribution for each unique product that we include in our portfolio.

We intend to engage third

party research and development firms who specialize in the creation of medical products to assist us in the development.

We will apply

for trademarks and patents as we develop proprietary products.

Financial Information about Industry Segments

We do not report our financial

results by segment.

See financial statements.

Our Growth Strategy

Once the U.S.

and Drug Administration (the “FDA”) clears us to market the CardioMap®

and Save a Life products, we intend to enter

into agreements with qualified distributors throughout the United States and internationally, including:

Europe, South America,

Africa, India and China.

We intend to require such distributors to pay us an initial license fee, as well as royalties based on

Retaining exclusivity, we will bill based on a mutually agreeable semi-annual or quarterly sales minimum.

determined to focus on international growth because, generally, such international license agreements provide a stronger path to

revenue and earnings than purely domestic products.

Our objective is to

grow revenue through marketing and sales of each of our products, CardioMap®

and Save a Life, once they gain regulatory approvals.

Although no assurances can be given, management anticipates company growth from the following areas:

If the FDA clears or approves

our product candidates, we intend to enter into agreements with qualified distributors throughout the United States.

A similar approach

will be pursued if our product candidates are cleared or approved for marketing outside of the United States.

We intend to require such

distributors to pay us an initial license fee, as well as royalties based on gross sales.

Retaining exclusivity, will be based on a mutually

agreeable semi-annual or quarterly sales minimum.

We have determined to focus on international growth because, generally, such international

license agreements provide a stronger path to revenue and earnings than purely domestic products.

Our objective is to grow revenue

through marketing and sales of each of our product candidates, CardioMap®

and Save a Life, if they gain regulatory approvals.

no assurances can be given, management anticipates company growth from the following areas:

1) Distribution or License Agreements.

In most cases, we will enter into distribution agreements with companies who have sales professionals with experience selling through a variety of sales methods.

These distribution agreements will allow us to more quickly achieve sales and revenue in the health products industries.

In most cases, we will enter into distribution agreements with

companies who have sales professionals with experience selling through a variety of sales methods.

These distribution agreements will

allow us to more quickly achieve sales and revenue in the health products industries.

2) Generate revenues from sales of CardioMap®

and Save a Life.

We intend to market CardioMap®

We intend to market

CardioMap®

and Save a Life through third party distributors and through our own efforts.

1 unchanged sentence

for additional proprietary uses of the product.

We intend to identify new areas of the human body to map utilizing CardioMap®

technology such as the brain, liver and kidney.

pursue development of CardioMap®

technology for use in other areas of the human body, such as the brain, liver and kidney.

4) The development and acquisition of new products.

We intend to market any new products that may be developed or acquired.

We intend, as capital resources permit, to develop such opportunities if and when they present themselves.

We intend to pursue development and acquisition

of other product candidates and market any new products, if cleared or approved.

We intend, as capital resources permit, to develop such

opportunities if and when they present themselves.

5) Seek partners to assist in the further development of our drug device combination products.

intend to seek partners to assist with the further development and clinical trials of both PRV-001 and PRV-002.

Partnerships could be

in the form of government grants or from industry pharmaceutical companies who have an interest in brain related drug therapies.

We currently have no products

authorized for commercial distribution in either the United States, Europe or any other country.

We are developing devices and pharmaceutical

drugs, which are in various stages of development, and which will require regulatory clearance or approvals and we cannot begin marketing

and selling our product candidates until we obtain applicable authorizations from the respective regulatory agency.

FDA clearance or approval

to market the products will be required to sell in the United States.

About CardioMap®

The CardioMap®

System will be an internet service based on the new development of Dispersion Mapping Method in ECG analysis for the

early, non-invasive testing of a heart disease (“CHD”).

The heart monitoring system is intended to provide high quality

3-D visualization and diagnosis of the heart using advanced signal analysis.

The product is being designed for use in a professional

setting or in remote settings including home use.

Once FDA cleared, CardioMap®

is intended to be a heart monitoring and screening device based on a novel method of Dispersion Mapping in ECG analysis for the early,

non-invasive testing for coronary heart disease (“CHD”).

The heart monitoring system is intended to provide high quality 3-D

visualization and diagnosis of the heart using advanced signal analysis.

The product is being designed for use in a professional setting

or in remote settings including in-home use.

We have exclusive, royalty free rights to USPTO patent number 7,519,416 B2 related to the

CardioMap technology.

FDA cleared or approved, CardioMap®

could provide a better level of diagnosis with its improved sensitivity levels that can detect early warning signs that would normally

be invisible with standard ECG devices.

The system is designed to dramatically cut the costs associated with the detection of ischemic

heart disease and will prove to be an invaluable testing device for cardiologists, physicians, clinics, hospitals, the fitness

industry, sports teams, emergency facilities and general public.

The system can dramatically cut the costs associated with the detection of ischemic heart disease

and will prove to be an invaluable testing device for cardiologists, physicians, clinics, hospitals, the fitness industry, sports teams,

emergency facilities and general public.

CardioMap®

was developed by VE Science Technology LLC, from

whom we have purchased the product rights.

In order to sell, market and distribute the CardioMap®

product, clearance from the

FDA is required.

Such clearance has not been obtained at this time.

Product Development

was developed by VE Science Technology LLC, from whom we have purchased the product

We have a working model of the device and associated software and plan to further develop the technology for clinical trials and

a 510K FDA submission.

To sell, market and distribute the CardioMap®

product, clearance or approval from the FDA is required.

clearance or approval has not been obtained at this time.

Product Development Plan:

Engineering Model

1 unchanged sentence

FDA Submission

The product development

plan is an estimate and is subject to change based on funding, technical risks and regulatory approvals.

This product development plan

is an estimate and is subject to change based on funding, technical risks and regulatory approvals.

About Save-a-Life®

In July of 2019 we purchased

all intellectual property including two patents for the choking rescue device:

patent Number RE45, 535 E and patent Number 8,454,624 B2.

The Save a Life®

(“SAL”) choking rescue device is in development and being designed to be a safe, and easy to use device for removing

a lodged mass or bolus from the throat of a choking victim.

The device includes a pump for creating a vacuum chamber, which is

connected seamlessly with a replaceable/disposable mouthpiece.

(“SAL”) choking rescue device is currently in development and being designed to be a safe, and easy to

use device for removing a lodged mass from the throat of a choking victim.

The device includes a pump for creating a vacuum chamber, which

is connected seamlessly with a replaceable/disposable mouthpiece.

In an emergency the SAL may be easily inserted into the victim’s

mouth, which depresses the tongue providing a clear application.

By pressing a button on the device, the device will deliver the

appropriate amount of instantaneous vacuum to dislodge the mass or bolus in the throat without harm or damage to the victim.

application will be instantly effective as the device is operational and effective in a matter of seconds.

In order to sell, market

and distribute the Save-a-Life product, clearance from the FDA is required.

Such clearance has not been obtained at this time.

The Development Plan for commercializing the Save-a-Life product is below.

Product Development

By pressing an activation button on the device, the internal pump is

intended to deliver the appropriate amount of instantaneous vacuum to dislodge the mass without harm or damage to the person.

The application

is intended to be instantly effective as the device will be operational and effective in a matter of seconds.

To sell, market and distribute

the Save-a-Life product, clearance or approval from the FDA is required.

Clinical trials for the device will be conducted on anatomically

correct models to demonstrate device performance.

The regulatory pathway is expected to be a 510k submission to the FDA once successful

clinical data is obtained.

FDA clearance or approval has not been obtained at this time.

The Development Plan for the Save-a-Life is below.

Product Development Plan

Engineering Model

1 unchanged sentence

FDA Submission

Complete –

in testing phase

Product development

plan are estimates only and are subject to change based on funding, technical risks and regulatory approvals.

The Save a Life

has a number of advantages and features.

The highlights are:

Easy to Use –

The product is designed to be used by adults and children.

The tongue depressor vacuum tube is inserted versus trying to place and keep a mask on a traumatized patient.

Management also believes the product can be self-administered.

Smart Patented Design - The product is designed specifically to immobilize the palate from reflex spasm and open the air passage using a replaceable tongue depressor vacuum tube.

A controlled vacuum action (manual or CO2 powered), with specific negative pressure, has been carefully calculated enabling the lifting of a lodged mass from the throat, so it may be ejected by reflexive coughing.

This device utilizes a negative pressure to gently uplift the object from the larynx, at which point it will be coughed upward and outward reflexively.

Used on Anyone –

The SAL is designed to be used on infants (20 months plus) to elderly adults.

Also, it can be use on pregnant women and others who the Heimlich maneuver cannot help.

Product Development Plan is

an estimate only and is subject to change based on funding, technical risks and regulatory approvals.

About the neurosteroid PRV-001

The Prevacus neurosteroid,

PRV-001 will seek to improve function and lifespan in pediatric disorders where de-myelination and cell death is widespread in

the cortex and cerebellum regions of the brain.

The neurosteroid, PRV-001,

is intended to improve function and lifespan in pediatric disorders where de-myelination and cell death is widespread in the cortex, subcortical

nuclei, brainstem and cerebellum regions of the brain.

The new chemical entity is designed to work through gene amplification to simultaneously

remove intra-neuronal debris while promoting antioxidant capacity and myelin repair/cell proliferation.

Disorders like Nieman Pick

Type C disease are multi-faceted in their pathology and require a treatment that can work at many levels to stop progression.

chemical compound for the neurosteroid being developed has completed initial safety tests in mice.

Toxicology studies have been

performed and show a 380-fold safety margin.

Preclinical efficacy studies show improvements in cognitive function and neuromotor

In order to sell the PRV-001 neurosteroid, further development and clinical studies are required.

PRV-001 will also

require approval by the FDA in order to be sold in the United States.

Product Development

Disorders like Nieman Pick Type

C disease are multi-faceted in their pathology and require a treatment that can work at many levels to stop progression.

compound for the neurosteroid being developed has completed an initial safety study in rats.

Results of preclinical studies suggest that

PRV-001 may improve neuromotor, cognitive and mental performance.

To sell the PRV-001 neurosteroid, further development and clinical studies

are required.

PRV-001 will also require approval by the FDA in order to be sold in the United States.

Per our agreement with Prevacus,

a Tallahassee, Florida based biotech company, we have fifty percent ownership in the drug compound and associated intellectual property.

There are issued patents covering methods of PRV-001 synthesis.

Product Development Plan for

Pre-clinical Animal Studies

FDA Submission

Safety study complete

The product development

plan is an estimate only and is subject to change based on funding, technical risks and regulatory approvals.

We believe that the

primary competition for our products and services is from existing companies offering EKG equipment and anti-choking devices, as

well as other pharmaceutical companies engaged in the development of Orphan drugs.

This product development plan

is an estimate and is subject to change based on funding, technical risks and regulatory approvals.

About the neurosteroid PRV-002

On March 1, 2021, we purchased

one hundred percent of the drug compound PRV-002 from Prevacus, Inc.

PRV-002 is a fully synthetic, non-naturally occurring neurosteroid

being developed for the treatment of mTBI (concussion).

Results of preclinical studies suggest that PRV-002 has equivalent, and potentially

superior, neuroprotective effects compared to related neurosteroids.

In animal models of concussion PRV-002 reduced the behavioral pathology

associated with brain injury symptoms such as short-term memory loss, depression/anxiety-like behavior and motor-sensory impairment.

drug is administered through the nasal passage from a novel device.

PRV-002 is lipophilic and can cross the blood-brain barrier thus supporting

its potential to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow through

gene amplification.

The drug has completed toxicology

studies in rat and dog.

Studies show that PRV-002 has a safety margin over 200X it’s predicted efficacious dose.

PRV-002 to date

has been shown to be stable up to 104 degrees for 6-months.

The drug candidate is currently being spray-dry manufactured into a powder

that will be filled into the novel breath-propelled nasal device developed by Odyssey.

The device is light weight and easy to use in the

Odyssey’s novel nasal device is breath-propelled causing the soft palate to close in the back of the nasopharynx.

This mechanism

traps PRV-002 in the nasal cavity allowing for a more abundant and faster drug availability in the traumatized brain.

Safety studies have

established a dosing regimen of 2X/day for fourteen (14) days.

Clinical Trial Phase I is site-set in Melbourne, Australia with a Contract

Research Organization (CRO), Nucleus Network Inc.

The country of Australia provides a twenty percent (20%) currency exchange advantage

and a 43.5% rebate at the end of our fiscal year from the Australian government on all Research and Development performed in Australia.

The trial is expected to begin in November 2021.

A comprehensive Investigator’s

Brochure has been created and submitted to the Alfred Ethics Committee by our CRO in Australia.

Approval has been granted to initiate

the phase 1 human trial and subjects have been enrolled.

The phase 1 trial will have two components to it, phase 1a and 1b.

designed to determine the safety profile of the drug in healthy human subjects.

Phase 1a will have forty-eight subjects using a Single

Ascending/Multiple Ascending (SAD/MAD) drug administration design.

For both the SAD and MAD portions there will be 4 groups, placebo,

low dose, middle dose and high dose.

All dosages are within the animal preclinical efficacy and safety range.

The SAD component is a 1X

treatment and the MAD component is a 1X/day treatment for 5-days.

Blood and urine samples will be collected at multiple time points for

safety pharmacokinetics.

Standard safety monitoring will be provided for each bodily system.

Phase 1b will begin following the completion

of the final safety report from Phase 1a establishing no safety concerns.

In Phase 1b PRV-002 will be administered to 24 acutely-concussed

patients, 2x a day for 14-days.

The trial will be low powered and evaluate safety as well as efficacy measurements to be used in Phase

2/3 clinical trials.

Based on the Phase 1a and 1b data we plan to submit an application for an Investigational New Drug with the FDA and

conduct a phase 2 trial in the United States.

Patents on PRV-002 have been

filed and/or issued:

Composition of matter for PRV-002 and analogs

Use for treating traumatic brain injury

Synthetic methods for PRV-002

Development Plan

Pre-clinical Animal Studies

Food and Drug

Administration Submission

September 2021

This product development plan

is an estimate and is subject to change based on funding, technical risks and regulatory approvals.

We believe that the primary

competition for our products and services is from existing companies offering EKG equipment and anti-choking devices, as well as other

pharmaceutical companies engaged in the development of Orphan drugs.

Governmental Regulation

Product Regulation

processing, formulation, safety, manufacturing, packaging, labeling, advertising and distribution of our products may be subject

to certain regulation by one or more federal agencies, including the FDA, Housing and Human Services (the “HHS”), the

Federal Trade Commission (the “FTC”), the Consumer Product Safety Commission (the “CPSC”), the United States

Department of Agriculture (the “USDA”) and the Environmental Protection Agency (the “EPA”), and by various

agencies of the states and localities in which our products are sold.

In order to sell, market

and distribute the CardioMap®, the Save a Life or the drug compound products, clearance or approval from the FDA is required.

Such clearance or approval has not been obtained at this time and our products are not currently available for commercial sale.

products we eventually sell in foreign countries are also subject to regulation under various national, local and international

laws that include provisions governing, among other things, the formulation, manufacturing, packaging, labeling, advertising and

distribution of drugs and medical products.

Government regulations in foreign countries may prevent or delay the introduction,

or require the reformulation, of some of our products.

At the date hereof,

we have three employees (one full-time and two part-time) and intend to hire additional employees in the foreseeable future.

The processing,

formulation, safety, manufacturing, packaging, labeling, advertising and distribution of our products may be subject to certain regulation

by one or more federal agencies, including the FDA, Housing and Human Services (the “HHS”), the Federal Trade Commission (the

“FTC”), the Consumer Product Safety Commission (the “CPSC”), the United States Department of Agriculture (the

“USDA”) and the Environmental Protection Agency (the “EPA”), and by various agencies of the states and localities

in which our products are sold.

To sell, market and distribute

the CardioMap®, the Save a Life or the drug compound products, clearance or approval from the FDA is required.

Such clearance or approval

has not been obtained at this time and our products are not currently available for commercial sale.

we eventually sell in foreign countries are also subject to regulation under various national, local and international laws that include

provisions governing, among other things, the formulation, manufacturing, packaging, labeling, advertising and distribution of drugs

and medical products.

Government regulations in foreign countries may prevent or delay the introduction, or require the reformulation,

of some of our products.

At the date hereof, we have

four employees and intend to hire additional employees in the foreseeable future.

Where you can find more information

The Company’s

Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to reports filed pursuant

to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), are filed with the

Securities and Exchange Commission (the “SEC”).

Such reports and other information filed by the Company with

the SEC are available free of charge on the Company’s website at http://www.odysseygi.com when such reports are

available on the SEC website.

The public may read and copy any materials filed by the Company with the SEC at the SEC’s Public

Reference Room at 100 F Street, NE, Room 1580, Washington, DC 20549.

The public may obtain information on the operation of the

Public Reference Room by calling the SEC at 1-800-SEC-0330.

The SEC maintains an Internet site that contains reports, proxy and

information statements and other information regarding issuers that file electronically with the SEC at www.sec.gov.

of these websites are not incorporated into this filing.

Further, the Company’s references to the URLs for these websites

are intended to be inactive textual references only.

Our Annual Report on Form

10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to reports filed pursuant to Sections 13(a) and 15(d)

of the Securities Exchange Act of 1934, as amended (“Exchange Act”), are filed with the U.S.

Securities and Exchange Commission

(the “SEC”).

Such reports and other information filed by us with the SEC are available free of charge on our website

at http://www.odysseygi.com when such reports are available on the SEC website.

The public may read and copy any materials filed

by us with the SEC at the SEC’s Public Reference Room at 100 F Street, NE, Room 1580, Washington, DC 20549.

The public may obtain

information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.

The SEC maintains an Internet site that

contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC at www.sec.gov.

The contents of these websites are not incorporated into this filing.

Further, our references to the URLs for these websites are intended

to be inactive textual references only.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 1. Business